Serotonergic dysfunction in patients with impulse control disorders in Parkinson’s disease
Brain · 03.06.2025 · 148 (6) · 2108-2121
DOI: 10.1093/brain/awaf087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 05.03.2025. Verfasst von Stéphane Prange und 11 weiteren Autor:innen. Beteiligte Einrichtung: Univ Lyon, Lyon Neuroscience Research Center (CRNL), CNRS UMR 5292, INSERM U1028, Bron F- 69675, France. Hauptthemen laut MEDLINE: Parkinson Disease, Disruptive, Impulse Control, and Conduct Disorders, Serotonin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fondation Neurodis, Association France Parkinson, Fondation pour la Recherche Médicale.
Abstract (Originalsprache)
Impulse control disorders (ICDs) are frequent and particularly distressing neuropsychiatric symptoms in patients with Parkinson’s disease, which are related to impaired behavioural inhibition. Multiple PET imaging studies indicate that striatal dopaminergic abnormalities contribute to hyperdopaminergic functioning in Parkinson’s disease patients with ICD (PDICD+) and to the dysregulation of the limbic fronto-striatal networks, which are critical for reward-related decision impulsivity. However, the serotonergic system is central to response inhibition and plays a critical role in neuropsychiatric symptoms in PD, but its role remains undetermined in PDICD. We hypothesized that PDICD+ patients exhibit serotonergic dysfunction within the cortico-striato-pallido-thalamic circuits involved in the inhibitory control of behaviour and decided to investigate the pre- and postsynaptic serotonergic innervation using two highly specific PET tracers for the serotonin transporter (SERT) using 11C-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile (11C-DASB) and the 5-HT2A receptor using 18F-altanserin. In this prospective, case-control, double-tracer PET study, we recruited 15 PDICD+ patients, 15 PDICD− patients and 15 healthy controls, matched for age and sex, and compared the availability of 11C-DASB and 18F-altanserin using permutation-based analysis. PDICD+ patients had one (n = 9) or multiple ICDs (n = 6), consisting of hypersexuality (n = 8), compulsive eating (n = 6), compulsive shopping (n = 5) and pathological gambling (n = 4), and were characterized by greater choice impulsivity (impaired delay discounting for monetary rewards) and greater urgency with more severe depressive and anxious symptoms. We demonstrate that PDICD+ patients had greater 11C-DASB binding in the posterior putamen and pallidum in comparison to PDICD− patients, corresponding to relatively preserved presynaptic SERT availability within the subcortical sensorimotor network involved in response inhibition. In addition, cortical 18F-altanserin binding was greater in PDICD+ patients in the bilateral supplementary motor area, precentral gyrus and right dorsolateral prefrontal cortex, involving the sensorimotor and associative networks which regulate behavioural inhibition. Furthermore, we show that pre- and postsynaptic serotonergic dysfunction subserving action versus decision impulsivity in patients with Parkinson’s disease specifically followed the distinctive functional organization of the sensorimotor and associative fronto-striatal networks. Altogether, we demonstrate that serotonergic dysfunction related to ICDs in Parkinson’s disease specifically involve the sensorimotor and associative cortico-striato-pallido-thalamic circuits involved in inhibitory control. Thus, serotonergic dysfunction contributes to the mechanisms related to the vulnerability and development of ICDs in patients with Parkinson’s disease, beyond the known dopaminergic abnormalities in the limbic fronto-striatal circuit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ Lyon, Lyon Neuroscience Research Center (CRNL), CNRS UMR 5292, INSERM U1028, Bron F- 69675, France.
- Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson NS-PARK/FCRIN network, Bron F-69500, France.
- Univ Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine et de Maïeutique Lyon Sud Charles Mérieux, Oullins F-69600, France.
- Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5284, INSERM U1314, MeLiS, Lyon F-69008, France.
- Hospices Civils de Lyon (HCL), Lyon F-69002, France.
- CERMEP-Imaging platform, Groupement Hospitalier Est, Bron F- 69677, France.
ORCID-Profile: Stéphane Prange, Véronique Sgambato
Förderung
- Fondation Neurodis
- Association France Parkinson
- Fondation pour la Recherche Médicale
- Alexander von Humboldt fellowship
Zitieren
APA
Prange, S., Metereau, E., Klinger, H., Huddlestone, M., De Oliveira, M., Duperrier, S., Courault, P., Redoute, J., Tremblay, L., Sgambato, V., Lancelot, S., & Thobois, S. (2025). Serotonergic dysfunction in patients with impulse control disorders in Parkinson’s disease. Brain, 148(6), 2108-2121. https://doi.org/10.1093/brain/awaf087
Vancouver
Prange S, Metereau E, Klinger H, Huddlestone M, De Oliveira M, Duperrier S, et al. Serotonergic dysfunction in patients with impulse control disorders in Parkinson’s disease. Brain. 2025;148(6):2108-2121. doi:10.1093/brain/awaf087
BibTeX
@article{Prange2025,
author = {Prange, Stéphane and Metereau, Elise and Klinger, Hélène and Huddlestone, Marine and De Oliveira, Melinda and Duperrier, Sandra and Courault, Pierre and Redoute, Jérôme and Tremblay, Léon and Sgambato, Véronique and Lancelot, Sophie and Thobois, Stéphane},
title = {Serotonergic dysfunction in patients with impulse control disorders in Parkinson’s disease},
journal = {Brain},
year = {2025},
volume = {148},
number = {6},
pages = {2108--2121},
doi = {10.1093/brain/awaf087}
}
EUVIMED